| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.04B | 10.87B | 9.34B | 8.05B | 6.99B | 4.31B |
| Gross Profit | 3.28B | 2.02B | 2.50B | 3.70B | 3.05B | 1.81B |
| EBITDA | 1.54B | 1.60B | 1.98B | 1.61B | 1.30B | 962.41M |
| Net Income | -5.14M | 62.22M | 840.77M | 677.01M | 541.25M | 423.96M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 17.04B | 16.08B | 12.81B | 11.94B | 9.97B |
| Cash, Cash Equivalents and Short-Term Investments | 1.29B | 1.29B | 1.08B | 2.16B | 2.02B | 1.29B |
| Total Debt | 0.00 | 4.76B | 3.78B | 1.81B | 1.74B | 541.27M |
| Total Liabilities | -9.95B | 7.08B | 6.00B | 3.54B | 3.17B | 1.62B |
| Stockholders Equity | 9.95B | 9.92B | 10.00B | 9.28B | 8.76B | 8.35B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -1.03B | -275.11M | 492.90M | -564.77M | 577.89M |
| Operating Cash Flow | 0.00 | -313.01M | 195.96M | 677.73M | 189.17M | 843.49M |
| Investing Cash Flow | 0.00 | -433.53M | 380.73M | -610.59M | -602.82M | -569.70M |
| Financing Cash Flow | 0.00 | 822.58M | -1.51B | -500.24M | 904.59M | -293.57M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | ₹16.86B | 25.45 | ― | 0.84% | 6.98% | -17.11% | |
65 Neutral | ₹25.95B | 34.75 | ― | 0.14% | 10.29% | 25.18% | |
64 Neutral | ₹30.59B | 41.23 | ― | 0.15% | 15.84% | 79.69% | |
63 Neutral | ₹25.65B | 31.39 | ― | 0.34% | 13.78% | 32.21% | |
58 Neutral | ₹26.62B | 1,145.00 | ― | 0.48% | 13.03% | -100.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | ₹26.56B | 231.39 | ― | ― | 11.80% | ― |
Shalby Multi-Specialty Hospitals has achieved a significant milestone by performing the world’s first fully autonomous robotic joint replacement surgery. This innovative technology, featuring a saw-based robotic arm with 7-axis movement, enhances surgical precision and reduces recovery time, reinforcing Shalby’s position as a leader in orthopedic innovation. The advancement is expected to benefit millions globally by providing safer and more precise surgeries.